Morgan Stanley lowered the firm’s price target on enGene (ENGN) to $18 from $19 and keeps an Overweight rating on the shares after the company reported Q3 results and reiterated clinical development timelines for detalimogene. The firm adjusting its model based on Q3 actual results drives its price target change, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Buy Rating for enGene Holdings: Strategic Positioning and Competitive Edge in NMIBC Market
- enGene Holdings Reports Q3 2025 Results and Milestones
- enGene Holdings Achieves Key Milestone in LEGEND Trial and Secures RMAT Designation
- enGene reports Q3 EPS 57c vs. 32c last year
- Citizens JMP healthcare analysts hold an analyst/industry conference call